Ajanta Pharma Limited
AJANTPHARM · General/Diversified · NSE
₹2,823
Current Market Price
Fair Value (DCF)
₹1,908
Margin of Safety
-32.4%
Updated 23h ago
YieldIQ Score
58/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
46%
ROE
24.3%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹0.35 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
30.1%
Return on capital employed
EV / EBITDA
24.1×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
58.4×
EBIT covers interest
Current Ratio
2.85×
Short-term liquidity
Asset Turnover
0.98×
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.1%
3-year revenue growth
Revenue CAGR (5Y)
12.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹2,822.7
Bear case
₹1,005.93
MoS -180.6%
Base case
₹1,908.21
MoS -47.9%
Bull case
₹2,261.24
MoS -24.8%
Ratio Trends
AJANTPHARM · last 8 annual periods
ROE
24.3%
ROCE
35.3%
Operating Margin
—
Debt / Equity
0.01×
PE
27.0×
EV / EBITDA
16.8×
Historical Financials
AJANTPHARM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹2719 Cr | ₹3341 Cr | ₹3411 Cr | ₹4209 Cr | ₹4588 Cr | +14.0% |
| EBITDA | — | ₹1045 Cr | ₹882 Cr | ₹1257 Cr | ₹1354 Cr | +6.7% |
| EBIT | ₹909 Cr | ₹920 Cr | ₹705 Cr | ₹1121 Cr | — | +5.4% |
| PAT | ₹676 Cr | ₹713 Cr | ₹559 Cr | ₹816 Cr | ₹920 Cr | +8.0% |
| EPS (diluted) | ₹77.59 | ₹82.45 | ₹43.61 | ₹64.77 | — | -4.4% |
| CFO | ₹467 Cr | ₹562 Cr | ₹736 Cr | ₹785 Cr | ₹1157 Cr | +25.5% |
| CapEx | — | — | — | — | ₹-318 Cr | — |
| FCF | — | — | — | — | ₹839 Cr | +0.0% |
| Total Assets | — | ₹4056 Cr | ₹4305 Cr | ₹4638 Cr | ₹5015 Cr | +5.5% |
| Total Debt | — | — | ₹0.0 Cr | ₹1.5 Cr | ₹47.4 Cr | — |
| Shareholders' Equity | — | — | ₹3246 Cr | ₹3567 Cr | ₹3790 Cr | +3.9% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
AJANTPHARM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| IPCALAB IPCALAB | — | — | Pending | 8.8% | — |
| JBCHEPHARM JBCHEPHARM | — | — | Pending | 19.2% | — |
| EMCURE EMCURE | — | — | Pending | 14.7% | — |
| GLAND Gland Pharma Limited | -12.7% | 64 | Near Fair Value | 7.6% | — |
| ABBOTINDIA ABBOTINDIA | — | — | Pending | 33.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
11 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹120.33/sh
Last payout
2025-11-10
₹28.00
Peak payout
₹28.00
Trailing yield
0.99%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Ajanta Pharma Limited (AJANTPHARM.NS) trades at 2822.70 vs a model fair value of 1908.21, a gap of -32.4%. Piotroski F-score: 7/9. Moat l...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of AJANTPHARM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for AJANTPHARM →
Compare
Head-to-head with peers
Compare AJANTPHARM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse AJANTPHARMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.